NeuroTherapeutics Pharma Receives Investment From The Epilepsy Therapy Project

NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

Go to Source

People who read this also read

• UF Researchers Get $250,000 to study Cell-Based Epilepsy Treatment
  University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults. Citizens United for Research in Epilepsy, also known as CUR...
• UF Researchers Get 250,000 Dollars To Study Cell-Based Epilepsy Treatment
  University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults. Citizens United for Research in Epilepsy, also known as CURE...
• Children With Epilepsy Say Their Quality Of Life Is Better Than Their Parents Think It Is
  Children with epilepsy and their parents have different perspectives of the impact of their illness on the child. Assessing quality of life is important for measuring endpoints in clinical trials of new therapies in children, particularly those with epilepsy, a common chronic neurological condition...
• First Publication Of Data From Pivotal Clinical Trial For Medtronic Deep Brain Stimulation Therapy For Epilepsy Published Today In Epilepsia
  Medtronic, Inc. (NYSE: MDT) today announced that a landmark publication highlighting results from the pivotal study for Medtronic Deep Brain Stimulation (DBS) Therapy for epilepsy, known as SANTE® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), was published online today in the me...
• Neurologix Receives Notice Of Allowance For Epilepsy Therapeutic Approach
  Neurologix, Inc. (OTCBB:NRGX) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (US PTO) for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application,...